Potential Antimalarial Activity of Artemether/Lumefantrine/Doxycycline: A Study in Mice Infected with Plasmodium berghei

Udeme Owunari Georgewill, Elias Adikwu

Abstract


Antimalarial drug resistance is one of the greatest challenges towards eradicating malaria. Exploring new combination therapies can overcome resistance challenges. The present study examined the antiplasmodial effect of artemether/lumefantrine/doxycycline (A/L/D) on a mouse model infected with Plasmodium berghei. Adult Swiss albino mice (22-30g) intraperitoneally infected with blood containing 1x107 Plasmodium berghei were randomly grouped and orally treated daily with D (2.2 mg/kg), A/L (1.71/13.7 mg/kg) and A/L/D. The negative control was treated daily with normal saline (0.2ml) whereas the positive control was treated daily with chloroquine (CQ) (10mg/kg). After treatment, blood samples were assessed for percentage parasitemia and biochemical parameters. Mice were observed for mean survival time (MST). D, A/L and A/L/D produced significant decreases in percentage parasitemia levels at p<0.05; p<0.01 and p<0.001, respectively when compared to negative control. In the curative test, D, A/L and A/L/D produced 60.4%, 70.3%, and 90.0% parasitemia inhibitions, respectively whereas CQ produced 76.0% parasitemia inhibition. D, A/L, A/L/D and CQ produced 63.2 %, 80.1%, 92.3% and 83.6% parasitemia inhibitions, respectively in the suppressive test. D, A/L, and A/L/D prevented Plasmodium berghei-induced alterations in biochemical parameters by increasing packed cell volume, red blood cells, hemoglobin, and high-density lipoprotein and decreasing white blood cells, total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels significantly at p<0.05 and p<0.01 and p<0.001, respectively when compared to the negative control. A/L/D produced significant antiplasmodial activity therefore, it may be used clinically for the treatment of malaria.

Keywords


Antiplasmodial; artemether; tetracycline; antimalarial; lumefantrine; Plasmodium berghei

Full Text:

PDF

References


Alecrim MG, Lacerda MV, Mourao MP, Alecrim WD, Padilha A, & Cardoso BS. (2016). Successful treatment of Plasmodium falciparum malaria with a six-dose regimen of artemether-lumefantrine versus quinine-doxycycline in the Western Amazon region of Brazil. American Journal of Tropical Medicine and Hygiene. 74: 20-5

Basco, L. K., & Le Bras J. (1993). Activity in vitro of doxycycline against multidrug-resistant Plasmodium falciparum. Transaction of Royal Society of Tropical Medicine and Hygiene. 87:469–470

Bobasa EM, Alemu BG, Berkessa ST, Gemechu Y, Fufa FG, & Cari GZ et al. 2018. Antimalarial activity of selected Ethiopian medicinal plants in mice. Journal of Pharmacy & Pharmacognosy Research, 6 (1), 57-64.

Cui L, Mharakurwa S, Ndiaye D, Rathod PK, & Rosenthal PJ. (2015). Antimalarial drug resistance literature review and activities and finding of the ICEMR network. American Journal of Tropical Medicine and Hygiene. 93(3):57–68

Gaillard T, Madamet M, & Pradines B. (2015). Tetracyclines in malaria. Malaria Journal. 14, 445 ;1-10.

Georgewill UD, Harold Melford H, & Adikwu E (2021). Antiplasmodial activity of artemether-lumefantrine-tinidazole on Plasmodium berghei infected mice. The Pharmaceutical and Chemical Journal, 2021, 8(1):107-113

Inbaneson SJ, & Sundaram R. (2012). In vitro antiplasmodial effect of ethanolic extracts of traditional medicinal plant Ocimum species against Plasmodium falciparum. Asian Pacific Journal of Tropical Medicine 5(2):103–106.

Institute for Laboratory Animal Research (ILAR). Guide for the care and use of laboratory animals. 8th ed. Washington DC: National Academic Press; 2011.

Khan MA, Smego RA Jr, Razi ST, & Beg MA. (2004). Emerging drug--resistance and guidelines for treatment of malaria. Journal of the College of Physicians and Surgeons of Pakistan.14: 319- 24

Knight, D.J, & Peters, W. (1980). The antimalarial action of N-Benzyl oxydihydrotriazines and the studies on its mode of action. Ann of Tropical Medicine and Parasitology. 74: 393-404.

Miller RS, Wongrichanalai C, Buathong N, McDaniel P, Walsh DS, & Knirsch C (2006). Effective treatment of uncomplicated Plasmodium falciparum malaria with azithromycin-quinine combinations: a randomized, dose-ranging study. American Journal of Tropical Medicine and Hygiene. 74: 401-6

Nardos A, & Makonnen E. (2017). In vivo antiplasmodial activity and toxicological assessment of hydroethanolic crude extract of Ajuga remota. Malaria Journal. 16:25; 1-8

Nsanzabana C. (2019). Resistance to Artemisinin Combination Therapies (ACTs): Do Not Forget the Partner Drug! Tropical Medicine and Infectious Disease. 4, 26;1-11

Oliveira AB, Dolabela MF, Braga FC, Jácome RLRP, Varotti FP, & Póvoa MM. (2009). Antimalarial Agents: New Leads and Efficient Phythomedicines. Part I. Alkaloids. Anais da Academia Brasileira de Ciências. 81:715–40.

Peters, W. (1967). Rational methods in the search for antimalarial drugs. Transaction of Royal. Society of Tropical Medicine and Hygiene. 61: 400-410.

Prapunwattana P, O’Sullivan WJ, & Yuthavong Y. (1988). Depression of Plasmodium falciparum dihydroorotate dehydrogenase activity in in vitro culture by tetracycline. Molecular and Biochemical Parasitology. 27:119–24.

Ryley, J.F, & Peters, W. (1970). The antimalarial activity of some quinolone esters. Annals of Tropical Medicine and Parasitology. 84: 209-222.

Schmidt KE, Kuepper JM, Schumak B, Alferink J, Hofmann A, & Hawland SW (2018). Doxycycline inhibits experimental cerebral malaria by reducing inflammatory immune reactions and tissue-degrading mediators. Public Library of Science One. 13:e0192717.

Sirima SB, Ogutu B, & Lusingu JPA. (2016). Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. Lancet Infectious Disease. 16(10):1123-1133.

Somsak V, Damkaew A, & Onrak P. (2018). Antimalarial Activity of Kaempferol and Its Combination with Chloroquine in Plasmodium berghei Infection in Mice. Journal of Pathology 2018; 2018;1- 7

Stover KR, King ST, & Robinson J. (2012). Artemether-lumefantrine: an option for malaria. Annalsof Pharmacotherapy. 46(4):567-77.

Unekwuojo EG, James O, & Olubunmi AR. (2011). Suppressive, curative and prophylactic potentials of Morinda lucida (Benth) against, erythrocytic stage of mice infected with Chloroquine sensitive Plasmodium berghei. British Journal of Applied Science and Technology. 1(3):131-40

Visser B.J, Wieten R.W, Nagel I.M. & Grobusch MP. (2013). Serum lipids and lipoproteins in malaria - a systematic review and meta-analysis. Malaria Journal. 12, 442, 1-16

White NJ, & Olliaro PL, (1996). Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitology Today 12: 399–401

World Health Organization. 2005. International travel and health, p. 132– 151. World Health Organization, Geneva, Switzerland

World Health Organization. 2001. Drug resistance in malaria

Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, & White NJ. (2004). Antimalarial drug resistance, artemisinin based combination therapy, and the contribution of modelling to elucidating policy choices. American Journal of Tropical Medicine and Hygiene. 71(2): 179-86




DOI: https://doi.org/10.14421/biomedich.2022.111.1-6

Refbacks

  • There are currently no refbacks.




Copyright (c) 2022 Udeme Owunari Georgewill, Elias Adikwu



Biology, Medicine, & Natural Product Chemistry
ISSN 2089-6514 (paper) - ISSN 2540-9328 (online)
Published by Sunan Kalijaga State Islamic University & Society for Indonesian Biodiversity.

Creative Commons License
This work is licensed under a CC BY-NC